VMO1 Antibody

What is VMO1 protein and why is it significant in research?

VMO1 (vitelline membrane outer layer 1 homolog) is a protein originally identified in chicken egg vitelline membrane, with homologs now recognized in mammals including humans, mice, and rats. The protein has a calculated molecular weight of approximately 22 kDa and consists of 202 amino acids .

The significance of VMO1 lies in its emerging role in various tissues. While initially characterized in avian reproductive biology, current research indicates expression in multiple human tissues, particularly in secretory organs. Research from immunohistochemical studies suggests VMO1 functions as a secreted protein, with detection reported in mouse inner ear and adult lung tissues . The gene is identified by GenBank accession number BC104195 and NCBI Gene ID 284013 .

Understanding VMO1's tissue distribution and function is critical for researchers investigating epithelial biology, secretory mechanisms, and potentially identifying novel biomarkers for diagnostic applications.

Which techniques are most effective for VMO1 protein detection?

Multiple validated techniques exist for VMO1 detection, with optimization requirements varying by sample type and research question:

For optimal results, researchers should consider:

• Sample-dependent titration is essential for achieving optimal signal-to-noise ratios

• Western blot analysis typically reveals the expected 22 kDa band corresponding to the VMO1 protein

• For immunohistochemistry, antigen retrieval methods significantly impact detection efficiency, with TE buffer pH 9.0 recommended as primary approach, though citrate buffer pH 6.0 offers an alternative

When selecting detection methods, researchers should consider the biological question, required sensitivity, and available sample types. Multiple detection methods applied in parallel often provide more robust validation of findings.

How should researchers validate commercial VMO1 antibodies for their specific applications?

Antibody validation requires a systematic, multi-parameter approach to ensure specificity and reproducibility:

• Positive and negative control tissues: Based on available data, use lung tissue (particularly A549 cells) as positive controls, as VMO1 expression has been confirmed in these cells through RNA extraction and PCR analysis . Include tissues known not to express VMO1 as negative controls.

• Knockout/knockdown validation: Where possible, compare antibody signals between wild-type samples and those where VMO1 has been genetically modified or silenced.

• Molecular weight verification: In Western blot applications, confirm detection of the expected 22 kDa band corresponding to the VMO1 protein .

• Cross-reactivity assessment: Test the antibody against related proteins to ensure specificity.

• Protocol optimization: For each application (WB, IHC, IF), optimize conditions including:

  • Antibody concentration (starting with manufacturer's recommendations)

  • Incubation times and temperatures

  • Blocking reagents

  • Detection systems

When troubleshooting validation issues, consider creating recombinant VMO1 protein as a definitive positive control. Research indicates that this approach is beneficial for conclusively demonstrating antibody specificity, particularly when multiple bands are observed in Western blots .

What are the optimal sample preparation methods for immunohistochemical detection of VMO1?

Immunohistochemical detection of VMO1 requires careful attention to fixation, embedding, and antigen retrieval procedures:

Fixation and Embedding Options:

• Paraffin embedding: Successfully used for VMO1 detection in multiple tissues with appropriate antigen retrieval

• OCT embedding for cryosections: Alternative approach particularly useful for preserving antigenicity in sensitive tissues

Antigen Retrieval Methods:
The primary recommended protocol uses TE buffer at pH 9.0, which has been empirically determined to provide optimal epitope exposure for VMO1 antibody binding. As an alternative, citrate buffer at pH 6.0 can be employed, though comparative studies suggest potentially reduced sensitivity .

Sectioning Considerations:
Both cryotome (for OCT-embedded samples) and microtome (for paraffin-embedded samples) approaches have been validated for VMO1 detection. Section thickness of 5-7 μm typically provides optimal results balancing structural integrity with antibody penetration .

Detection System Selection:
For fluorescence detection, secondary antibodies conjugated to bright, photostable fluorophores are recommended. The VMO1 antibody is available with Allophycocyanin conjugation (e.g., Novus Biologicals NBP2-97300APC), enabling direct fluorescence detection without secondary antibodies .

Researchers should conduct parallel processing of positive control tissues (such as lung or kidney) alongside experimental samples to validate staining procedures.

How can researchers troubleshoot multiple bands in VMO1 Western blots?

Multiple bands in VMO1 Western blots have been reported in the literature and require systematic troubleshooting:

• Protein degradation assessment: Include freshly prepared samples with protease inhibitors to determine if additional bands represent degradation products.

• Post-translational modification analysis: VMO1 may undergo glycosylation or other modifications that alter migration patterns. Consider enzymatic deglycosylation treatments prior to electrophoresis.

• Antibody specificity verification:

  • Use peptide competition assays to confirm specificity

  • Compare results with alternative VMO1 antibodies targeting different epitopes

  • Consider the development of recombinant VMO1 protein as a definitive control

• Loading and transfer optimization:

  • Adjust protein loading amounts (typically 20-50 μg total protein)

  • Optimize transfer conditions for low molecular weight proteins

  • Consider using gradient gels for better resolution

• Alternative antibody dilutions: Test a range of concentrations (1:500-1:1000 recommended for WB applications)

Research has noted that commercial VMO1 antibodies may require validation to demonstrate specific target epitope recognition, with recombinant protein production recommended as a definitive approach to address specificity concerns .

What expression systems are suitable for recombinant VMO1 protein production?

Creating recombinant VMO1 protein is valuable for antibody validation and protein-protein interaction studies. Several expression systems have been investigated:

Prokaryotic Expression:
E. coli-based expression has been successfully employed for human VMO1 fragment production. This approach facilitated the creation of immunogens for antibody production . Key considerations include:

• Selection of appropriate vectors (pPLUG vector has been documented for VMO1 cloning)

• Transformation protocols for competent E. coli cells

• Screening methods including colony PCR and DNA sequencing to confirm proper insertion

Mammalian Expression:
Given the potential for post-translational modifications, mammalian expression systems may provide more physiologically relevant VMO1 protein. Human lung cell line A549 has been documented as expressing VMO1 and could serve as a source for gene amplification .

Cloning Strategy:

• Extract RNA from VMO1-expressing tissues (lung cells A549 recommended)

• Convert to cDNA via reverse transcription

• Amplify VMO1 using PCR with specific primers

• Ligate into appropriate expression vector

• Transform into competent E. coli cells

• Select positive colonies through antibiotic resistance

• Verify construct via colony PCR and sequencing

For protein-protein interaction studies, creation of tagged VMO1 constructs (e.g., His-tag, FLAG-tag) is recommended to facilitate purification and detection in downstream applications.

What is currently known about the tissue distribution of VMO1 in humans?

Understanding VMO1 tissue distribution is essential for contextualizing experimental findings. Current evidence indicates:

Confirmed Expression:

• Lung tissue: RNA expression confirmed in A549 lung cells through PCR analysis

• Kidney tissue: Protein expression detected through immunohistochemistry with validated antibodies

• Cell lines: Expression demonstrated in HeLa and HEK-293 cells

Methodology for Expression Profiling:
Researchers have employed multiple complementary approaches to characterize VMO1 distribution:

• RNA extraction and RT-PCR from diverse tissue samples

• cDNA synthesis and PCR amplification using VMO1-specific primers

• Validation of expression through immunohistochemistry and Western blotting

• Confirmation of protein localization via immunofluorescence

For researchers investigating novel tissues, a multi-modal approach combining mRNA detection (RT-PCR) with protein validation (IHC/WB) is recommended to conclusively establish expression patterns.

How can researchers design protein-protein interaction studies involving VMO1?

Investigating VMO1's interacting partners is crucial for understanding its biological function. Several methodological approaches are appropriate:

Recombinant Expression Systems:
Creating a human VMO1 expression clone has been documented as an effective starting point. This involves:

• Amplifying VMO1 from lung cells (A549)

• Ligating the VMO1 insert into appropriate vectors (pPLUG vector reported)

• Transforming competent E. coli cells

• Selecting positive colonies through antibiotic resistance markers

• Confirming sequence integrity through DNA sequencing

Interaction Screening Approaches:

• Pull-down assays: Using tagged recombinant VMO1 as bait

• Co-immunoprecipitation: With validated VMO1 antibodies

• Yeast two-hybrid screening: For discovery of novel interactions

• Proximity labeling methods: BioID or APEX2 fusion proteins for in vivo interaction mapping

Validation Strategies:

• Reverse co-immunoprecipitation with antibodies against identified partners

• Colocalization studies using immunofluorescence microscopy

• Functional assays to determine the biological significance of identified interactions

For researchers planning interaction studies, creating expression constructs with different epitope tags would facilitate both expression verification and downstream purification for various interaction detection methodologies .

What storage and handling practices ensure optimal VMO1 antibody performance?

Proper storage and handling of VMO1 antibodies is critical for maintaining reactivity and specificity:

Storage Conditions:

• Store at -20°C for long-term stability

• Antibody remains stable for one year after shipment when stored properly

• Aliquoting is not necessary for -20°C storage for the 21577-1-AP antibody

Buffer Composition:

• Typical storage buffer consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• Some small-volume preparations (20μl) contain 0.1% BSA as a stabilizer

Thawing and Handling:

• Thaw antibodies on ice or at 4°C

• Avoid repeated freeze-thaw cycles

• Centrifuge briefly after thawing to collect contents at the bottom of the vial

• Maintain cold chain during experimental setup

• Return to -20°C promptly after use

Working Dilution Preparation:

• Prepare working dilutions fresh on the day of experiment

• Use high-quality diluents free of contaminants

• For Western blot applications, prepare at 1:500-1:1000 dilution

• For immunohistochemistry and immunofluorescence, prepare at 1:20-1:200 dilution

Adherence to these practices will help ensure reproducible results and maximize the usable lifetime of VMO1 antibodies.

How should researchers address cross-reactivity concerns with VMO1 antibodies?

Cross-reactivity assessment is essential for ensuring the specificity of VMO1 antibody-based findings:

Species Cross-Reactivity:
Commercial VMO1 antibodies have demonstrated reactivity with human, mouse, and rat samples . When working with other species, researchers should perform validation studies before proceeding with full experiments.

Testing for Non-Specific Binding:

• Negative controls: Include tissues known not to express VMO1

• Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding

• Secondary-only controls: Omit primary antibody to assess non-specific binding of detection systems

• Isotype controls: Use matched concentration of irrelevant antibody of same isotype

Addressing Cross-Reactivity in Multi-Color Immunofluorescence:

• Test each antibody individually before combining

• Include single-color controls in multiplexed experiments

• Consider using directly conjugated antibodies (such as Allophycocyanin-conjugated VMO1 antibody) to reduce secondary antibody cross-reactivity issues

Validation in Western Blot:
Evaluate specificity by confirming detection of the expected 22 kDa band. When multiple bands appear, consider developing recombinant VMO1 protein as a definitive control to establish antibody specificity .

What are the emerging applications of VMO1 antibodies in biomedical research?

VMO1 antibodies are finding increasing utility across several research domains:

Inner Ear Research:
Immunohistochemical studies have detected VMO1 in P5 mouse inner ear, suggesting potential roles in auditory system development or function . This finding opens possibilities for investigating:

• VMO1's role in hearing development

• Potential involvement in auditory disorders

• Comparative analysis across species

Respiratory System Studies:
Detection in mouse adult lung and human lung cell lines (A549) indicates potential roles in respiratory epithelial biology . Research applications include:

• Investigation of secretory functions in airway epithelia

• Studies of lung development and differentiation

• Exploration of potential roles in respiratory pathologies

Secretory Protein Investigations:
Evidence suggests VMO1 functions as a secreted protein , prompting research into:

• Secretion mechanisms and regulation

• Extracellular functions and protein-protein interactions

• Potential roles as biomarkers in biological fluids

Protein Structure-Function Studies:
As understanding of VMO1's biological roles expands, structure-function studies using recombinant protein and antibody tools become increasingly valuable for:

• Identifying functional domains through mutagenesis

• Characterizing post-translational modifications

• Developing inhibitors or modulators for functional studies

The continuing development and validation of VMO1 antibodies will facilitate these emerging research directions.

How can researchers integrate VMO1 antibody data with other molecular techniques?

Maximizing research impact requires integrating antibody-based detection with complementary molecular approaches:

Multi-Omics Integration:

• Transcriptomics: Correlate protein detection with RNA-seq or qPCR data to understand expression regulation

• Proteomics: Combine antibody-based detection with mass spectrometry for comprehensive protein characterization

• Genomics: Associate VMO1 genetic variations with protein expression patterns

Functional Validation Approaches:

• Gene silencing/knockout: Compare antibody signals before and after VMO1 depletion

• Overexpression studies: Assess effects of increased VMO1 expression on cellular functions

• Live-cell imaging: Combine with fluorescently-tagged VMO1 to visualize dynamics

Technical Complementation:

• Use in situ hybridization alongside immunohistochemistry to correlate mRNA and protein localization

• Combine ELISA quantification with Western blot analysis for both quantitative and qualitative assessment

• Integrate immunoprecipitation with mass spectrometry for interactome characterization

Data Analysis Integration:

• Develop computational workflows that integrate antibody-based imaging data with other molecular data types

• Apply machine learning approaches to identify patterns across multi-modal datasets

• Establish reproducible pipelines for consistent data generation and interpretation

This integrated approach provides more robust findings than any single technique alone, particularly for novel proteins like VMO1 where biological functions remain under investigation.

What future directions should researchers consider for VMO1 antibody applications?

As VMO1 research evolves, several promising directions emerge for antibody-based investigations:

• Development of monoclonal antibodies: While current research primarily uses polyclonal antibodies , development of monoclonals targeting specific VMO1 epitopes would enhance reproducibility and specificity.

• Expanded tissue distribution studies: Comprehensive profiling across human tissues would clarify physiological roles and potential disease associations.

• Functional domain mapping: Creating antibodies targeting specific domains could elucidate structure-function relationships.

• Secretion pathway investigations: Given evidence of VMO1 as a secreted protein , antibodies could help track secretory mechanisms and extracellular functions.

• Species-comparative studies: Developing cross-species reactive antibodies would facilitate evolutionary and comparative biology studies.

• Post-translational modification characterization: Modification-specific antibodies could identify regulatory mechanisms affecting VMO1 function.

• Development of therapeutic applications: As biological functions become clearer, antibody-based therapies might be explored for VMO1-associated conditions.